organ damage
Vicore announces initiation of proof-of-concept study for endothelial dysfunction treatments
May 4, 2023Research and Development Cardiology, Vicore Pharma, clinical trials, endothelial dysfunction, organ damage
Vicore Pharma Holding AB has announced that it has dosed the first patient with C21 in its randomised, double-blind, placebo-controlled, …
